A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
1027
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor's Decision
Conditions
Alzheimer's Disease
Interventions
DRUG:
Aducanumab
DRUG:
Placebo
Sponsor
Biogen